Cytomegalovirus (CMV) Treatment Market - By Drug Type (Valganciclovir, Ganciclovir, Cidofovir, Foscarnet), Application, Route of Administration, Distribution Channel - Global Forecast, 2024

Description

Cytomegalovirus (CMV) Treatment Market size is expected to expand at 6.6% CAGR during 2024-2032, driven by advancements in medical technology and diagnostic techniques along with the rising awareness about early detection and treatment options.

Organ transplant recipients and individuals with HIV/AIDS have grown susceptible to CMV infections due to their weakened immune systems. With the increasing number of organ transplantations performed globally and the rising prevalence of HIV/AIDS cases, the demand for effective CMV treatment options is on the rise. As per UNOS (United Network for Organ Sharing), in 2022, over 42,800 organ transplants were performed, setting a new annual record.

Healthcare providers are also recognizing the importance of preventing and managing CMV infections in this vulnerable patient population to improve clinical outcomes and reduce the risk of complications. Consequently, there is a growing need for innovative therapies and treatment strategies tailored to address the unique challenges posed by CMV infection in organ transplant and HIV/AIDS patients, thereby driving the market growth.

The CMV treatment market is classified based on drug type, distribution channel, route of administration, application, and region.

The industry size from the cidofovir drug type segment is expected to record 6.8% growth rate till 2032, as the drug inhibits viral DNA replication, making it an effective antiviral agent against CMV infections. The broad-spectrum activity and favorable safety profile have positioned cidofovir as a preferred choice for CMV treatment, particularly in immunocompromised patients. Furthermore, benefits like extended half-life to offer less frequent dosing for enhancing patient compliance and convenience will add to the segment growth.

Cytomegalovirus treatment market from the E-commerce platform distribution channel segment may witness 6.5% CAGR up to 2032, owing to the convenience, accessibility, and discretion offered by online pharmacies. E-commerce platforms often provide a wide range of product choices, competitive pricing, and doorstep delivery, further enhancing their appeal to consumers. The growing trend of online purchasing, coupled with the increasing penetration of internet and smartphone technologies has also fueled the expansion of e-commerce in the healthcare sector.

Asia Pacific CMV treatment market is poised to depict 7% CAGR during 2024-2032, driven by increasing healthcare expenditure, rising awareness about infectious diseases, and expanding healthcare infrastructure. Countries, such as China, India, and Japan are expected to lead the market expansion, fueled by large patient population and the growing demand for effective CMV treatment options. Furthermore, government initiatives aimed at improving healthcare accessibility and affordability along with favorable regulatory policies are creating conducive environments for industry growth in the region.

Product Code: 8288

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameter
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rise in the prevalence of cytomegalovirus infection
  - 3.2.1.2 Growing awareness and introduction of new drug therapies
  - 3.2.1.3 High prevalence of infectious diseases among AIDS patients
  - 3.2.1.4 Upsurge in patient pool of CMV retinitis and congenital CMV infection
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Adverse effects associated with cytomegalovirus drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
- 3.5.1 Supplier power
- 3.5.2 Buyer power
- 3.5.3 Threat of new entrants
- 3.5.4 Threat of substitutes
- 3.5.5 Industry rivalry
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Valganciclovir
5.3 Ganciclovir
5.4 Cidofovir
5.5 Foscarnet
5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Stem cell transplantation
6.3 Organ transplantation
6.4 Congenital CMV infection
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Intravenous

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Chimerix, Inc.
10.2 Clinigen Group PLC
10.3 F. Hoffmann-La Roche Ltd
10.4 Fresenius Kabi
10.5 Genentech Inc.
10.6 Gilead Sciences, Inc.
10.7 Merck & Co. Inc
10.8 Mylan N.V
10.9 Pfizer, Inc.
10.10 Takeda Pharmaceuticals
10.11 Teva Pharmaceuticals Inc
10.12 Thermo Fisher Scientific Inc.

Cytomegalovirus (CMV) Treatment Market - By Drug Type (Valganciclovir, Ganciclovir, Cidofovir, Foscarnet), Application, Route of Administration, Distribution Channel - Global Forecast, 2024 - 2032